Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jun;5(6):525.
doi: 10.1016/S2468-1253(20)30085-6. Epub 2020 Mar 25.

Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak

Fabiana Zingone  1 , Edoardo Vincenzo Savarino  2
Affiliations
Comment

Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak

Fabiana Zingone et al. Lancet Gastroenterol Hepatol. 2020 Jun.
No abstract available

PubMed Disclaimer

Comment on

  • Implications of COVID-19 for patients with pre-existing digestive diseases.
    Mao R, Liang J, Shen J, Ghosh S, Zhu LR, Yang H, Wu KC, Chen MH; Chinese Society of IBD, Chinese Elite IBD Union; Chinese IBD Quality Care Evaluation Center Committee. Mao R, et al. Lancet Gastroenterol Hepatol. 2020 May;5(5):425-427. doi: 10.1016/S2468-1253(20)30076-5. Epub 2020 Mar 11. Lancet Gastroenterol Hepatol. 2020. PMID: 32171057 Free PMC article. No abstract available.

References

    1. Mao R, Liang J, Shen J. Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet Gastroenterol Hepatol. 2020 doi: 10.1016/S2468-1253(20)30076-5. published online March 11. - DOI - PMC - PubMed
    1. 1st Interview COVID-19 ECCO Taskforce ECCO Crisis Task Force. March 13, 2020. https://www.ecco-ibd.eu/images/6_Publication/6_8_Surveys/1st_interview_C...
    1. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108:1268–1276. - PubMed
    1. Osterman MT, Sandborn WJ, Colombel JF. Crohn's disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab. Am J Gastroenterol. 2016;111:1806–1815. - PubMed
    1. Singh S, Murad MH, Fumery M. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol. 2020 doi: 10.1016/j.cgh.2020.01.008. Published online Jan 13. - DOI - PMC - PubMed

Substances

LinkOut - more resources